Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS1-1-01 in moderate to severe depression
NCT06259526Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JS1-1 in major depressive disorder (MDD) (5 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Change in Montgomery-Åsberg Depression Rating Scale total score from baseline at 8 weeks. Started Dec 2023; status: completed.
02
Drugs
JS1-1
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06259526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259526.